Aibo Medical Technology Co., Ltd. Reports Standardized Management of 2025 Raised Funds and Steady Progress in Contact Lens Production Line Construction

China Visit Network DataEyebright Medical Technology (Beijing) Co., Ltd. (hereinafter referred to as "Eyebright MedicalEyebright Medical successfully completed a private placement of shares in April 2025, raising approximately 281 million yuan in net proceeds. According to the company's 2025 Special Report on the Depository and Use of Raised Funds, as of December 31, 2025, the balance in the special account for raised funds was approximately 209 million yuan. During the reporting period, the raised funds were mainly used for the "Contact Lens and Injection Mold Processing Production Line Construction Project" and to supplement working capital. The company has used approximately 39.2392 million yuan of the raised funds to replace self-raised funds previously invested in the fundraising projects. To ensure proper management, the company signed a regulatory agreement with the sponsor institution and the supervisory bank to guarantee that the funds are deposited in a dedicated account and used exclusively for their intended purpose. Additionally, the company’s board of directors approved a proposal to manage up to 150 million yuan of idle raised funds through cash management to improve fund utilization efficiency, but the balance of such cash management was zero at the end of the reporting period. Meanwhile, the company passed a resolution to provide a loan of no more than 260 million yuan from the raised funds to its holding subsidiary, Jiangsu Tianyan Medicine Technology Co., LTD, specifically for implementing the above-mentioned contact lens production line construction project. Overall, Eyebright Medical’s deposit, management, and use of the 2025 raised funds complied with relevant regulatory requirements, and the fundraising projects proceeded as planned.